Anaptysbio (ANAB) Preferred Stock Liabilities (2016)

Anaptysbio (ANAB) reported Preferred Stock Liabilities of $40.7 million for Q4 2016.

Anaptysbio (ANAB) Preferred Stock Liabilities (2016) Analysis & Trends

Anaptysbio has reported Preferred Stock Liabilities for 1 years, with the latest figure at $40.7 million in Q4 2016.

For the quarter ending Q4 2016, Preferred Stock Liabilities changed N/A year-over-year to $40.7 million; the trailing twelve-month figure through Dec 2016 stood at $40.7 million (changed N/A YoY), and the FY2016 full-year result was $40.7 million, changed N/A from the prior year.
Preferred Stock Liabilities for Q4 2016 stood at $40.7 million.
The five-year high for Preferred Stock Liabilities was $40.7 million in Q4 2016, with the low at $40.7 million in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Anaptysbio	1.66 Bn	1.38 Bn	-	-

Download Data

Date	Value
Dec 31, 2016	40.69 Mn